Regulatory Focus A Chinese-based manufacturer of heparin products has been sent a Warning Letter by the US Food and Drug Administration (FDA) after regulators accused the company of preventing FDA inspectors from accessing the facility earlier this year, and possibly ...
The Biological SCENE A research team led by Jayachandran N. Kizhakkedathu of the University of British Columbia recently designed a reversal agent for heparin (Sci. Tr...
FiercePharma Manufacturing After tainted Chinese heparin in 2008 led to dozens of deaths of dialysis patients in the U.S., global regulators started preaching loud and clear on the need for heparin makers to be able to track back sources to ensure they were safe. German meat ...
MedPage Today Across five countries, hospital costs per patient were a median of $39,508 with dalteparin (Fragmin) compared with $40,805 on unfractionated heparin , Rob...
In-PharmaTechnologist.com Heparin production may be moving back to Europe according to the EFCG, which cited the opening of Pharma Action's processing plant as an indication that API buyers value quality and compliance throughout the supply chain. and more »
